Firibastat in Treatment-resistant Hypertension

Last updated: October 18, 2022
Sponsor: Quantum Genomics SA
Overall Status: Completed

Phase

3

Condition

Circulation Disorders

Stress

Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT04277884
QGC001-3QG1
  • Ages > 18
  • All Genders

Study Summary

This is a double-blind, placebo-controlled, multicenter, efficacy and safety study of firibastat (QGC001) administered po bid over 12 weeks in male and female subjects ≥18 years of age at Screening, with uncontrolled primary HTN. Subjects will be randomized 1:1 to investigational product (IP) and will receive either firibastat (QGC001) or matching placebo on top of their current chronic antihypertensive treatments.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men and women ≥18 years of age at Screening
  • Diagnosis of primary HTN for at least 6 months prior to Screening

Exclusion

Exclusion Criteria:

  • Known or suspected secondary HTN (eg, hyperaldosteronism, renovascular HTN,pheochromocytoma, Cushing's disease).
  • Automated office SBP >180 mmHg or DBP >110 mmHg at the Screening or Inclusion Visit (Visit 2, Day 1) and confirmed by a second measurement within 30 minutes to 1 hour.
  • Known hypertensive retinopathy (Keith-Wagener Grade 3 or Grade 4) and/or hypertensiveencephalopathy.

Study Design

Total Participants: 515
Study Start date:
June 25, 2020
Estimated Completion Date:
September 20, 2022

Study Description

The primary objective of this study is to assess the effects of administration of firibastat (QGC001) 500 mg oral (po) twice daily (bis in die [bid]) on blood pressure (BP) over 12 weeks in subjects with uncontrolled primary HTN.

Connect with a study center

  • Fakultní nemocnice v Motole

    Prague, 15006
    Czechia

    Site Not Available

  • Les Hôpitaux Universitaires de Strasbourg

    Strasbourg, Grand Est 67091
    France

    Site Not Available

  • Universitätsklinikum Schleswig-Holstein - Campus Kiel

    Kiel, 24105
    Germany

    Site Not Available

  • Ambulatorium Barbara Bazela

    Elbląg, Żuławy 82300
    Poland

    Site Not Available

  • Hospital Universitario de La Princesa

    Madrid, 280006
    Spain

    Site Not Available

  • Central Alabama Research

    Birmingham, Alabama 35209-8401
    United States

    Site Not Available

  • Marvel Clinical Research

    Huntington Beach, California 92647
    United States

    Site Not Available

  • Orange County Research Center

    Tustin, California 92780
    United States

    Site Not Available

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida 32216
    United States

    Site Not Available

  • Progressive Medical Research

    Port Orange, Florida 32127
    United States

    Site Not Available

  • Cardiovascular Center of Sarasota

    Sarasota, Florida 34239
    United States

    Site Not Available

  • Apex Medical Research

    Chicago, Illinois 60607
    United States

    Site Not Available

  • Cedar Crosse Research Center

    Chicago, Illinois 60607
    United States

    Site Not Available

  • ClinEdge - Chear Center

    Bronx, New York 10455
    United States

    Site Not Available

  • Sterling Research Group - Cincinnati / Mount Auburn

    Cincinnati, Ohio 45219
    United States

    Site Not Available

  • Insearch - Punzi Medical Center

    Carrollton, Texas 75006
    United States

    Site Not Available

  • ClinEdge - Dayton Clinical Research

    Dayton, Texas 45406-5144
    United States

    Site Not Available

  • Juno Research - Corporate Office

    Houston, Texas 77040
    United States

    Site Not Available

  • Insearch - R&H Clinical Research

    Katy, Texas 77450
    United States

    Site Not Available

  • Manassas Clinical Research Center

    Manassas, Virginia 20110
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.